The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.
 
Charles Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Jazz Pharmaceuticals; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Royalties related to licensing of anti-DLL3 antibodies.
 
Giannis Mountzios
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/Greece; BMS GmbH & Co. KG; MSD; Novartis; Roche; Takeda
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Demo Pharmaceutical; Ipsen; MSD; Novartis; Roche
 
Longhua Sun
No Relationships to Disclose
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Umut Demirci
Honoraria - Abdi Ibrahim; AstraZeneca; AstraZeneca; BMS Turkey; CTGEN; Daiichi Sankyo/Astra Zeneca; Gen; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; Merck Serono; MSD; Novartis; Roche; Sandoz
Consulting or Advisory Role - Gilead Sciences; Menarini; MSD; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Gen; Pfizer
 
Sofia Baka
Research Funding - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Regeneron; Roche; Zymeworks
 
Mahmut Gumus
Honoraria - Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)
Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)
Research Funding - Amgen (Inst); MSD Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Antonio Lugini
No Relationships to Disclose
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - A&D Pharma; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MagnaPharm; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; SERVIER; Takeda
Travel, Accommodations, Expenses - A&D Pharma; Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Servier
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Pedro Rocha
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Kyowa Kirin; MSD; Roche
 
Bo Zhu
No Relationships to Disclose
 
Fiona Blackhall
Honoraria - Amgen; AstraZeneca; AstraZeneca; Bayer; Medivation; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; AstraZeneca; Blueprint Medicines; cell Medica; Janssen; Medivation; Pfizer
Speakers' Bureau - AstraZeneca; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines; Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Celgene; Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Tatsuya Yoshida
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD Oncology; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Taofeek Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Heat Biologics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Meryx Pharmaceuticals; Novartis; PharmaMar; Puma Biotechnology; Roche/Genentech; Takeda; Triptych Health Partners; Xcovery
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Shuang Huang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Diana Gauto
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Gonzalo Recondo
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Speakers' Bureau - Janssen Oncology; Pfizer; Takeda
Research Funding - Amgen (Inst); Janssen (Inst)
 
Martin Schuler
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson/Janssen; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunocore; Johnson & Johnson/Janssen; MSD; Novartis; Regeneron; Roche; Sanofi; Tacalyx
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)